Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genprex Inc (NQ: GNPX )

0.9000 +0.0600 (+7.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 89,438
Open 0.8494
Bid (Size) 0.8950 (4)
Ask (Size) 0.9000 (1)
Prev. Close 0.8400
Today's Range 0.8000 - 0.9060
52wk Range 0.7358 - 2.670
Shares Outstanding 48,025,324
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Statement Regarding FDA Initiative to Accelerate Approval Process for Gene Therapies
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Barcelona Conference
Via Investor Brand Network

Performance

YTD
-43.40%
-43.40%
1 Month
-35.25%
-35.25%
3 Month
-10.00%
-10.00%
6 Month
-36.17%
-36.17%
1 Year
-62.03%
-62.03%

More News

Read More
Genprex’s Gene Therapy: Potential Breakthrough for Diabetes and Lung Cancer
Via News Direct
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Management to Participate in Two Upcoming Conferences
Via Investor Brand Network
S&P 500 Rises Over 0.5%; US Pending Home Sales Increase Sharply
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Rises 80 Points; TEGNA Shares Plunge
Via Benzinga
Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $4M Registered Direct Offering
Via Investor Brand Network
Why Genprex Shares Are Getting Hammered Today
Via Benzinga
TDOC Stock Alert: What to Know as SVB Securities Upgrades Teladoc
Via InvestorPlace
Genprex (GNPX) Stock Moves on Promising Diabetes Treatment Data
Via InvestorPlace
Why Enovix Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Inks Deal with University of Pittsburgh for Exclusive License to Diabetes Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Gene Therapy Treatment Data to be Presented at Upcoming International Diabetes Conference
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial, Licenses Additional Technology from University of Pittsburgh
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Gene Therapies for Cancer and Diabetes at Upcoming Conference
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Upcoming Investor, Industry Conferences
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CFO to Present Pioneering Gene Therapies at Upcoming Conference
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures New Patent, Critical Protection for REQORSA(TM) Combination Therapy
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.